[1] WHO. Coronavirus disease (COVID-2019) situation reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. [2020-03-12].https://www.who.int/emergencies/diseases/novel-coronavirus-2019
[2] Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 2020;26(6):845 − 8. http://dx.doi.org/10.1038/s41591-020-0897-1CrossRef
[3] Wang XL, Guo XH, Xin QQ, Pan Y, Hu YL, Li J, et al. Neutralizing antibody responses to severe acute respiratory syndrome coronavirus 2 in coronavirus disease 2019 inpatients and convalescent patients. Clin Infect Dis 2020. http://dx.doi.org/10.1093/cid/ciaa721CrossRef
[4] Zhao JJ, Yuan Q, Wang HY, Liu W, Liao XJ, Su YY, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis 2020. http://dx.doi.org/10.1093/cid/ciaa344CrossRef
[5] Li G, Chen XJ, Chen WS, Dai ZY, Chong YT, Yang L, et al. Variation in the titer of the specific IgG antibody in patients with SARS. J Trop Med 2003;3(3):283-5. http://lib.cqvip.com/Qikan/Article/Detail?id=8348675&from=Qikan_Search_Index. (In Chinese). http://lib.cqvip.com/Qikan/Article/Detail?id=8348675&from=Qikan_Search_Index
[6] Park WB, Perera RAPM, Choe PG, Lau EHY, Choi SJ, Chun JY, et al. Kinetics of serologic responses to mers coronavirus infection in humans, South Korea. Emerg Infect Dis 2015;21(12):2186 − 9. http://dx.doi.org/10.3201/eid2112.151421CrossRef
[7] Tipples GA, Hamkar R, Mohktari-Azad T, Gray M, Parkyn G, Head C, et al. Assessment of immunoglobulin M enzyme immunoassays for diagnosis of measles. J Clin Microbiol 2003;41(10):4790 − 2. http://dx.doi.org/10.1128/JCM.41.10.4790-4792.2003CrossRef
[8] Wu F, Wang AJ, Liu M, Wang QM, Chen J, Xia S, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv 2020. http://dx.doi.org/10.1101/2020.03.30.20047365.http://dx.doi.org/10.1101/2020.03.30.20047365
[9] Callaway E. Coronavirus vaccines: five key questions as trials begin: some experts warn that accelerated testing will involve some risky trade-offs. Nature 2020;579(780):481. http://dx.doi.org/10.1038/d41586-020-00798-8CrossRef
[10] Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med 2020;26(7):1033 − 6. http://dx.doi.org/10.1038/s41591-020-0913-5CrossRef
[11] Chang SC, Wang JT, Huang LM, Chen YC, Fang CT, Sheng WH, et al. Longitudinal analysis of severe acute respiratory syndrome (SARS) coronavirus-specific antibody in SARS patients. Clin Diagn Lab Immunol 2005;12(12):1455 − 7. http://dx.doi.org/10.1128/CDLI.12.12.1455-1457.2005CrossRef
[12] Lee N, Chan PKS, Ip M, Wong E, Ho J, Ho C, et al. Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndrome. J Clin Virol 2006;35(2):179 − 84. http://dx.doi.org/10.1016/j.jcv.2005.07.005CrossRef
[13] Zhang LQ, Zhang FW, Yu WJ, He T, Yu J, Yi CE, et al. Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals. J Med Virol 2006;78(1):1 − 8. http://dx.doi.org/10.1002/jmv.20499CrossRef
[14] Fu YJ, Cheng YX, Wu YT. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sin 2020;35(3):266 − 71. http://dx.doi.org/10.1007/s12250-020-00207-4CrossRef
[15] Jin YF, Yang HY, Ji WQ, Wu WD, Chen SY, Zhang WG, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses 2020;12(4):372. http://dx.doi.org/10.3390/v12040372CrossRef